Noah Freeman Shroyer

Noah Freeman Shroyer

Auto-generated profile, based on publicly available information

Noah Freeman Shroyer

Department of Medicine, Baylor College of Medicine

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2010 in Nature
Verified
Journal Article
Closed access
PDF file
TSToshiro Sato
Toshiro Sato
JEJohan H. van Es
Johan H. van Es
HSHugo J. Snippert
Hugo J. Snippert
DSDaniel E. Stange
Daniel E. Stange
RVRobert G. Vries
Robert G. Vries
HCHans Clevers
Hans Clevers

12 December 2010 in Nature
Verified
Journal Article
Open access
PDF file
JSJason R. Spence
Jason R. Spence
CMChristopher N. Mayhew
Christopher N. Mayhew
SRScott A. Rankin
Scott A. Rankin
MKMatthew F. Kuhar
Matthew F. Kuhar
JVJefferson E. Vallance
Jefferson E. Vallance
JWJames M. Wells
James M. Wells
Using a sequence of growth-factor manipulations to mimic embryonic intestinal development in culture, a new study has successfully generated human intestinal tissue in vitro from embryonic and induced pluripotent stem cells. The resulting epithelium was uniformly intestinal, with villus-like structures and progenitor domains, and contained all of the functional cell types of the gut, including brush borders that were indistinguishable from adult intestine. This approach may provide therapeutic benefit for disease studies. Using a temporal series of growth factor manipulations to mimic embryonic intestinal development in culture, this study has successfully directed the differentiation of human pluripotent stem cells (both embryonic stem cells and induced pluripotent stem cells) into intestinal tissue. This approach may provide therapeutic benefit for disease studies. Studies in embryonic development have guided successful efforts to direct the differentiation of human embryonic and induced pluripotent stem cells (PSCs) into specific organ cell types in vitro1,2. For example, human PSCs have been differentiated into monolayer cultures of liver hepatocytes and pancreatic endocrine cells3,4,5,6 that have therapeutic efficacy in animal models of liver disease7,8 and diabetes9, respectively. However, the generation of complex three-dimensional organ tissues in vitro remains a major challenge for translational studies. Here we establish a robust and efficient process to direct the differentiation of human PSCs into intestinal tissue in vitro using a temporal series of growth factor manipulations to mimic embryonic intestinal development10. This involved activin-induced definitive endoderm formation11, FGF/Wnt-induced posterior endoderm pattering, hindgut specification and morphogenesis12,13,14, and a pro-intestinal culture system15,16 to promote intestinal growth, morphogenesis and cytodifferentiation. The resulting three-dimensional intestinal ‘organoids’ consisted of a polarized, columnar epithelium that was patterned into villus-like structures and crypt-like proliferative zones that expressed intestinal stem cell markers17. The epithelium contained functional enterocytes, as well as goblet, Paneth and enteroendocrine cells. Using this culture system as a model to study human intestinal development, we identified that the combined activity of WNT3A and FGF4 is required for hindgut specification whereas FGF4 alone is sufficient to promote hindgut morphogenesis. Our data indicate that human intestinal stem cells form de novo during development. We also determined that NEUROG3, a pro-endocrine transcription factor that is mutated in enteric anendocrinosis18, is both necessary and sufficient for human enteroendocrine cell development in vitro. PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development and disease.

1 March 1997 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RARando Allikmets
Rando Allikmets
NSNanda Singh
Nanda Singh
HSHui Sun
Hui Sun
NSNoah F. Shroyer
Noah F. Shroyer
AHAmy Hutchinson
Amy Hutchinson
JLJames R. Lupski
James R. Lupski

9 December 2015 in Nature
Verified
Journal Article
Open access
PDF file
CLCaroline A. Lindemans
Caroline A. Lindemans
MCMarco Calafiore
Marco Calafiore
AMAnna M. Mertelsmann
Anna M. Mertelsmann
MOMargaret H. O’connor
Margaret H. O’connor
JDJarrod A. Dudakov
Jarrod A. Dudakov
AHAlan M. Hanash
Alan M. Hanash
Innate lymphoid cells increase the growth of mouse intestinal organoids via IL-22 production; recombinant IL-22 promotes growth of both mouse and human organoids, and promotes mouse intestinal stem cell (ISC) expansion and ISC-driven organoid growth via a STAT3-dependent pathway and independently of Paneth cells; IL-22 treatment in vivo enhances the recovery of ISCs from intestinal injury. The cellular signals supporting normal epithelial intestine maintenance through regulation of intestinal stem cell (ISC) activity are well characterized, but the signals involved in the regulation of the ISC compartment after damage are still unclear. Alan Hanash and colleagues have found that innate lymphoid cells produce interleukin-22 (IL-22) after injury to increase the growth of mouse intestinal organoids. They further show that recombinant IL-22 promotes ISC expansion in both human and mouse organoids, via a STAT3-dependent pathway and independently of the Paneth cells, which provide for ISC maintenance signals. IL-22 treatment also enhanced the recovery of ISCs from intestinal injury. Epithelial regeneration is critical for barrier maintenance and organ function after intestinal injury. The intestinal stem cell (ISC) niche provides Wnt, Notch and epidermal growth factor (EGF) signals supporting Lgr5+ crypt base columnar ISCs for normal epithelial maintenance1,2. However, little is known about the regulation of the ISC compartment after tissue damage. Using ex vivo organoid cultures, here we show that innate lymphoid cells (ILCs), potent producers of interleukin-22 (IL-22) after intestinal injury3,4, increase the growth of mouse small intestine organoids in an IL-22-dependent fashion. Recombinant IL-22 directly targeted ISCs, augmenting the growth of both mouse and human intestinal organoids, increasing proliferation and promoting ISC expansion. IL-22 induced STAT3 phosphorylation in Lgr5+ ISCs, and STAT3 was crucial for both organoid formation and IL-22-mediated regeneration. Treatment with IL-22 in vivo after mouse allogeneic bone marrow transplantation enhanced the recovery of ISCs, increased epithelial regeneration and reduced intestinal pathology and mortality from graft-versus-host disease. ATOH1-deficient organoid culture demonstrated that IL-22 induced epithelial regeneration independently of the Paneth cell niche. Our findings reveal a fundamental mechanism by which the immune system is able to support the intestinal epithelium, activating ISCs to promote regeneration.

19 September 1997 in Science
Verified
Journal Article
Open access
PDF file
RARando Allikmets
Rando Allikmets
NSNoah F. Shroyer
Noah F. Shroyer
NSNanda Singh
Nanda Singh
JSJohanna M. Seddon
Johanna M. Seddon
RLRichard Alan Lewis
Richard Alan Lewis
MLMark Leppert
Mark Leppert
Age-related macular degeneration (AMD) is the leading cause of severe central visual impairment among the elderly and is associated both with environmental factors such as smoking and with genetic factors. Here, 167 unrelated AMD patients were screened for alterations in ABCR , a gene that encodes a retinal rod photoreceptor protein and is defective in Stargardt disease, a common hereditary form of macular dystrophy. Thirteen different AMD-associated alterations, both deletions and amino acid substitutions, were found in one allele of ABCR in 26 patients (16%). Identification of ABCR alterations will permit presymptomatic testing of high-risk individuals and may lead to earlier diagnosis of AMD and to new strategies for prevention and therapy.

7 March 2011 in Journal of Cell Biology
Verified
Journal Article
Open access
FGFrançois Gerbe
François Gerbe
JEJohan H. van Es
Johan H. van Es
LMLeila Makrini
Leila Makrini
BBBénédicte Brulin
Bénédicte Brulin
GMGeorg Mellitzer
Georg Mellitzer
PJPhilippe Jay
Philippe Jay
The unique morphology of tuft cells was first revealed by electron microscopy analyses in several endoderm-derived epithelia. Here, we explore the relationship of these cells with the other cell types of the intestinal epithelium and describe the first marker signature allowing their unambiguous identification. We demonstrate that although mature tuft cells express DCLK1, a putative marker of quiescent stem cells, they are post-mitotic, short lived, derive from Lgr5-expressing epithelial stem cells, and are found in mouse and human tumors. We show that whereas the ATOH1/MATH1 transcription factor is essential for their differentiation, Neurog3, SOX9, GFI1, and SPDEF are dispensable, which distinguishes these cells from enteroendocrine, Paneth, and goblet cells, and raises from three to four the number of secretory cell types in the intestinal epithelium. Moreover, we show that tuft cells are the main source of endogenous intestinal opioids and are the only epithelial cells that express cyclooxygenase enzymes, suggesting important roles for these cells in the intestinal epithelium physiopathology.